Oncotarget

Research Papers:

Molecular insights into the OGG1 gene, a cancer risk modifier in BRCA1 and BRCA2 mutations carriers

Carlos Benitez-Buelga, Tereza Vaclová, Sofia Ferreira, Miguel Urioste, Lucia Inglada-Perez, Nora Soberón, Maria A. Blasco, Ana Osorio and Javier Benitez _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:25815-25825. https://doi.org/10.18632/oncotarget.8272

Metrics: PDF 832 views  |   HTML 1237 views  |   ?  


Abstract

Carlos Benitez-Buelga1, Tereza Vaclová1, Sofia Ferreira1, Miguel Urioste2,5, Lucia Inglada-Perez3,5, Nora Soberón4, Maria A. Blasco4, Ana Osorio1,5, Javier Benitez1,5

1Human Genetics Group, Spanish National Cancer Research Center (CNIO), Madrid 28029, Spain

2Familial Cancer Clinical Unit, Spanish National Cancer Research Center (CNIO), Madrid 28029, Spain

3Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid 28029, Spain

4Telomere and Telomerase Group, Spanish National Cancer Research Center (CNIO), Madrid 28029, Spain

5Spanish Network on Rare Diseases (CIBERER), Madrid 28029, Spain

Correspondence to:

Javier Benitez, e-mail: jbenitez@cnio.es

Keywords: BRCA1 and BRCA2, telomere shortening, OGG1 polymorfism, cancer risk modifier, DNA damage

Received: January 28, 2016     Accepted: March 07, 2016     Published: March 22, 2016

ABSTRACT

We have recently shown that rs2304277 variant in the OGG1 glycosidase gene of the Base Excision Repair pathway can increase ovarian cancer risk in BRCA1 mutation carriers. In the present study, we aimed to explore the role of this genetic variant on different genome instability hallmarks to explain its association with cancer risk.

We have evaluated the effect of this polymorphism on OGG1 transcriptional regulation and its contribution to telomere shortening and DNA damage accumulation. For that, we have used a series of 89 BRCA1 and BRCA2 mutation carriers, 74 BRCAX cases, 60 non-carrier controls and 23 lymphoblastoid cell lines (LCL) derived from BRCA1 mutation carriers and non-carriers.

We have identified that this SNP is associated to a significant OGG1 transcriptional down regulation independently of the BRCA mutational status and that the variant may exert a synergistic effect together with BRCA1 or BRCA2 mutations on DNA damage and telomere shortening.

These results suggest that this variant, could be associated to a higher cancer risk in BRCA1 mutation carriers, due to an OGG1 transcriptional down regulation and its effect on genome instability.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8272